vialaudit
TB-500·INDIANA·LAST CHECKED 1 NOV 2026

Is TB-500 legal in Indiana?

CAVEATS APPLY

Since 1 Jul 2026 Indiana law (IC 16-42-22.5) bars compounding from research-grade or veterinary-grade bulk ingredients outside an IRB-approved study and requires an FDA-registered source with a certificate of analysis. From 1 Jan 2027 medical spas must register with the state medical board. This matters if FDA later allows pharmacies to compound TB-500: in Indiana the ingredient could not be research grade. Federally: Not as a drug. TB-500 has no FDA approval, so selling it for human use breaks federal drug law, and a 'research use only' label does not protect a seller whose site signals human use. It is not a controlled substance, and possessing it is not a federal crime. Under an interim HHS policy of 28 October 2026, a licensed pharmacy may compound it against a prescription, by set routes and under strict conditions, without federal enforcement. That policy does not cover research-use-only vials sold online.

CATEGORY · NO APPROVAL

Full status breakdown

FEDERAL · STATE · SPORT-BODY

Federal status

FDA approval
no approval
DEA scheduling
not scheduled
503A compounding
FDA interim category: Nominated but withdrawn (off Category 2, not eligible)
503A Bulks List: pcac recommended
HHS interim policy (Oct 28, 2026): no enforcement against licensed 503A compounding with a prescription · routes: subcutaneous or intramuscular (acetate) · FEDERAL REGISTER ↗
Still not on the 503A Bulks List and not an approved drug. Removed from Category 2 on 15 Apr 2026. On 23 Jul 2026 the PCAC recommended it for the Bulks List (wound healing). On 28 Oct 2026 HHS issued an interim 'Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances' (Federal Register 30 Oct 2026, 91 FR 68526). HHS says it does not intend to take enforcement action against a state-licensed pharmacy, Federal facility or licensed physician compounding TB-500 against a patient-specific prescription, limited to subcutaneous or intramuscular, as a single ingredient, from API made by an FDA-registered facility with a full certificate of analysis. The Federal Register notice calls the policy a draft that is not binding; comments close 13 Nov 2026 (docket HHS-OASH-2026-0496). It does not cover 503B outsourcing facilities or research-use-only vials sold online.
PCAC review history
  • Jul 23, 2026 · recommended · 8 yes, 6 no, 1 abstention (law-firm reports) · SOURCE ↗
FDA Warning Letters
  • Jun 12, 2023 — Warrior Labz SARMs (cited: tb-500, bpc-157) · LETTER ↗
  • Feb 7, 2024 — US Chem Labs (cited: tb-500) · LETTER ↗
Shortage status
not currently on shortage list
Sale framing
Research-use-only posture: FDA rejects RUO defense for TB-500; Warrior Labz and US Chem Labs are direct precedents.
Personal possession: Not federally scheduled; not federally criminalized for end-user possession. Seller risk is high.

Indiana — state-specific

compounding restriction · Indiana

Since 1 Jul 2026 Indiana law (IC 16-42-22.5) bars compounding from research-grade or veterinary-grade bulk ingredients outside an IRB-approved study and requires an FDA-registered source with a certificate of analysis. From 1 Jan 2027 medical spas must register with the state medical board. This matters if FDA later allows pharmacies to compound TB-500: in Indiana the ingredient could not be research grade.

Sport-body status

WADA 2026
prohibited · class S2.3 · in and out of competition
Named: 'Thymosin-beta4 and its derivatives e.g. TB-500' under S2.3 growth factors.
USADA
NCAA

What we couldn’t verify

Also known as

5 ALIASES

TB-500 is also marketed or referenced under the following names (vendor pseudonyms, brand names, chemical identifiers):

  • Thymosin Beta-4 fragment
  • TB4 fragment
  • TB-500 acetate
  • Thymosin β4 fragment 17-23
  • LKKTETQ peptide

Related

FOLLOW-ONS

TB-500: US status, sources and what changed

THE ROUNDUP · MONTHLY

Receipts in your inbox. Once a month.

New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.

14,200 SUBSCRIBERS·0 SPONSORED ITEMS·11 ISSUES SINCE LAUNCH